UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2016

APTEVO THERAPEUTICS INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware	**001-37746**	**81-1567056**
(State or Other Jurisdiction of Incorporation	**(Commission File Number)**	**(IRS Employer Identification No.)**

2401 4th Avenue, Suite 1050 **Seattle, Washington** **(Address of Principal Executive Offices)**	**98121** **(Zip Code)**

Registrant's telephone number, including area code: (206) 838-0500

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Aptevo Therapeutics Inc. ("Aptevo") has prepared investor presentation materials with information about Aptevo, which it intends to use as part of investor presentations. A copy of the investor presentation materials to be used by management for presentations is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

APTEVO THERAPEUTICS INC.

Date: August 8, 2016

By: /s/ Shawnte Mitchell
Shawnte Mitchell, Secretary, Vice President and General Counsel

EXHIBIT INDEX

Exhibit Number	Exhibit Description
99.1	Presentation of Aptevo Therapeutics Inc. dated August 8, 2016

August 2016

Aptevo Therapeutics

Investor Presentation

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance, and any other statements containing the words "believes", "expects", "anticipates", "intends", "plans", "forecasts", "estimates" and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development, regulatory approvals or expenditures are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this presentation, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on Aptevo's business operations, assets or financial results as a result of the separation; a deterioration in the business or prospects of Aptevo; adverse developments in Aptevo's customer-base or markets; our ability to enter into and maintain selective collaboration and partnership arrangements; the timing of and our ability to achieve milestones in collaboration and partnership contracts; our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; and our commercialization, marketing and manufacturing capabilities and strategy and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including Aptevo's Registration Statement on Form 10, as amended.

The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

AGENDA

Leadership in Bispecific Antibody Development

- Aptevo today
- What sets us apart
- Summary

Aptevo: At a Glance

Focus	Oncology/Hematology
Commercial Products	4
Product Pipeline	Clinical: 2 Preclinical: Multiple
Platform Technologies	ADAPTIR™
Employees	~130
Headquarters	Seattle, WA
Q1 2016 Revenue	$8M
2015 Revenue	$33.6M
Cash Runway	$100M $65M cash (as of 8/4/16) $20M EBS future contribution $15M 2nd tranche (term loan)

Leading Oncology Platform

- Innovative ADAPTIR platform technology utilizing a promising approach in the highly attractive immuno-oncology field

Leveraging Technology

- Targeted investments in bispecific ADAPTIR therapeutics
- Increased awareness of the RTCC Mechanism of Action

Strong IP Estate

- Will own or exclusively license patent rights for entire product portfolio
- Will seek exclusive licenses for supporting technologies

Executive Leadership

Senior Management

Marvin White – President & CEO
Former Emergent Director; Former CFO, St. Vincent's Health; Former Exec. Director & CFO, Lilly USA

Jeff Lamothe – SVP, CFO
Former Emergent VP, Finance; Former CFO, Cangene Corporation

Randy Maddux – SVP, Operations
Former VP, Global Mfg & Supply, GSK;
Former VP, Mfg Ops & Quality, Human Genome Sciences

Dr. Scott Stromatt – SVP, CMO
Former Emergent SVP, CMO; Former CMO, Trubion

Dr. Jane Gross – VP, Res/Non-Clin. Dev.
Emergent VP, Research/Non-Clinical Development;
Former VP Immunology Research ZymoGenetics Inc.

Mike Adelman – VP, Commercial Ops.
Former Emergent VP, Commercial Operations; Former, VP Commercial Operations, Cangene Corporation

Shawnte Mitchell – VP, Gen'l Counsel
Former Emergent VP, Associate General Counsel

Board of Directors

Marvin White
Former Emergent Director; Former CFO, St. Vincent's Health; Former Exec. Director & CFO, Lilly USA

Fuad El-Hibri
Founder, Executive Chairman, Emergent BioSolutions

Daniel Abdun-Nabi
President & CEO, Emergent BioSolutions

Grady Grant, III
Mead Johnson Nutrition; Eli Lilly & Co.

Zsolt Harsanyi, Ph.D.
N-Gene Research Labs; Exponential Biotherapies; Porton Int'l

Barbara Lopez Kunz
DIA; Battelle; Thermo Fisher Scientific; ICI/Uniqema

John Niederhuber, M.D.
Inova Translational Medicine Institute; NCI; Johns Hopkins Univ.

Deep R&D, Commercial and Financial Expertise and Experience

Our Capabilities



Expertise and Leadership in Bispecific Antibody Development Facilitates Rapid Drug Development from Concept to Clinic

Our Strategy

1. Advance novel ADAPTIR™ product candidates, primarily in I/O
2. Expand collaborations and partnerships
3. Maximize cash flow from commercial portfolio to support R&D funding

AGENDA

Leadership in Bispecific Antibody Development

- Aptevo today
- What sets us apart
- Summary

Robust and Diversified Product Portfolio

Product/Candidate	Technology	Indication	Pre-Clinical	Clinical Development Stage			Marketed	Milestones/Highlights
				Phase I	Phase II	Phase III		
IXINITY	*Recombinant Protein*	*Hemophilia B*						$1.0M WW in 2015
WinRho	*Hyper Immune*	*ITP*						$14.2M WW in 2015
HepaGam B	*Hyper Immune*	*HBV*						$10.3M WW in 2015
VARIZIG	*Hyper Immune*	*Varicella*						$2.3M WW in 2015
Otlertuzumab	*ADAPTIR Monospecific*	*CLL*						Executing combination clinical trials
MOR209/ES414*	*ADAPTIR Bispecific RTCC*	*mCRPC Immuno-oncology*						Executing Phase 1 clinical trial
ES425	*ADAPTIR Bispecific RTCC*	*Hematological, Solid Tumor Malignancies*						Preclinical in vitro and in vivo POC, developing lead candidate
Multiple ADAPTIR Candidates	*ADAPTIR Bispecific*	*Hematological, Solid Tumor Malignancies*						Multiple RTCC candidates and ADAPTIR with novel MOA
ES210	*ADAPTIR Targeted cytokine*	*IBD*						Preclinical POC in IBD , CHO production cell line
5E3 mAb	*Monoclonal Antibody*	Alzheimer's Disease						Pursuing partnerships

RTCC – Redirected T-Cell Cytotoxicity

** Partnered with MorphoSys AG*

Commercial Products to Support R&D Funding

[coagulation factor IX (recombinant)]

An intravenous recombinant human coagulation factor IX therapeutic for use in patients with Hemophilia B

US: [Rh$_0$ (D) Immune Globulin Intravenous (Human)] Canada: (Rh$_0$(D) Immune Globulin (Human) for injection)

Immune Thrombocytopenic Purpura (ITP) and suppression of Rhesus (Rh) isoimmunization

US: [Hepatitis B Immune Globulin Intravenous (Human)] Canada: (Hepatitis B Immune Globulin (Human) Injection)

Prevention of hepatitis B recurrence following liver transplantation in HBsAg-positive patients and post exposure prophylaxis after acute hepatitis B exposure

US: VARIZIG® [Varicella Zoster Immune Globulin (Human)] Canada: VariZIG® (Varicella Zoster Immune Globulin (Human))

Post-exposure prophylaxis of varicella zoster in high risk individuals

ADAPTIR™ – Proprietary Platform Technology

MODULAR

- New bispecifics readily assembled with potent preclinical activity
- Ultimate flexibility; able to generate candidates with novel MOA
- Single chain format optimized for CHO cell production; avoids issues found with other bispecifics

VERSATILE

- Redirected T-Cell Cytotoxicity (RTCC)
- Targeted Cytokine Delivery
- Potential for additional MOAs

ADAPTABLE

- Applicable to a variety of solid and hematologic cancers, i.e.: breast, lung, ovarian, prostate, kidney, melanoma, pancreatic

SYNERGISTIC

- Potential for single, sequential, or combination immunotherapeutic approaches

Bispecific ADAPTIR™ Therapeutic



ADAPTIR™ RTCC

Key Advantages vs Other Bispecifics

Highly potent	**Induce target-dependent cytotoxicity at low concentrations in preclinical studies**
Longer Half Life	**Longer half-life in preclinical studies supports less frequent administration**
Reduced Toxicity	**Induce low levels of cytokine engagement of target cells in preclinical studies**
Ease of Manufac-turing	**Improved stability & physical characteristics GMP manufacturing up to 2000L scale**
Improved Economics	**mAB-like manufacturing advantages "Off the shelf" technology vs "cell-based" therapies**

Mechanism of Action

ADAPTIR Bispecific Molecules Mediate RTCC: Potent Immunotherapeutic for Cancer



ADAPTIR™

Clinical Pipeline

Product Candidate	Technology	Indication	Pre-Clinical	Clinical Development Stage			Milestones Highlights
				Phase I	Phase II	Phase III	
Otlertuzumab	*ADAPTIR Monospecific*	*CLL*					Executing combination clinical trials
MOR209/ES414*	*ADAPTIR Bispecific RTCC*	*mCRPC Immuno-oncology*					Executing Phase 1 clinical trial

RTCC – Redirected T-Cell Cytotoxicity

** Partnered with MorphoSys AG*

ADAPTIR™

Clinical Stage Candidate – otlertuzumab (CLL)

αCD37 scFv

Human IgG_1 Fc

Description

- Humanized monospecific protein therapeutic
- Targeting the CD37 signaling pathway involved in B-cell malignancies
- Built on ADAPTIR™ (modular protein therapeutic) platform
- Demonstrated anti-tumor activity
- Prolonged serum half-life (mouse /NHP) vs antibody fragments

Partnering

- 100% owned by Aptevo
- Actively pursuing potential partnership opportunities

Development Status

- Ongoing: Phase 2 Study for chronic lymphocytic leukemia (CLL)
- Planning: Combination study
- Multiple clinical trial data published at ASH 2013, establishing clinical proof-of-concept
  - PHASE 2 STUDY (16201): Combination of otlertuzumab and bendamustine in patients with relapsed CLL produced higher response rates than bendamustine alone
  - PHASE 1b STUDY (16009): Combination of otlertuzumab and rituximab in patients with previously untreated CLL was active and well tolerated

ADAPTIR™

Clinical Stage Candidate – MOR209/ES414 (mCRPC)

Anti-PSMA



Anti-CD3

Description

- Humanized bispecific protein therapeutic
- Targeting PSMA and CD3, a component of the T-cell receptor
- Demonstrated redirection of T-cells to kill tumor cells expressing PSMA in vitro and in vivo
- Prolonged serum half-life (mouse/NHP) vs antibody fragments

Partnering

- Co-development/Co-commercialization partnership with MorphoSys AG established August 2014

Development Status

- Open-label Phase 1 Study underway (U.S. & Australia)
- Safety, tolerability, and clinical activity in patients with metastatic castration-resistant prostate cancer (mCRPC) to be conducted in 2 stages
  - Stage 1: Primary Objective -- identify MTD administered intravenously. Secondary Objectives -- evaluate tolerability, PK, PD, immunogenicity, cytokine response, and clinical activity
  - Stage 2: Primary Objective -- evaluate clinical activity in patients that have or have not received prior chemotherapy

ADAPTIR™

Novel Preclinical Product Pipeline

Validated Platform Technology:

- *Bispecific ADAPTIR molecules can redirect T-cell cytotoxicity against multiple tumor targets in preclinical models*

Modular Bispecific Platform:

- *ADAPTIR platform can be used to generate bispecifics with novel MOA in Immuno-oncology and other diseases*

Molecule	Target Antigen Type	Target Indication(s)	Development Activity				
			Design	*in vitro* RTCC	*in vivo* POC	Tox/IND	Clinical: Phase 1
αROR-1 x αCD3 ES 42 5	Tyrosine Kinase (ROR-1)	Hematologic malignancies; solid tumors					
RTCC Candidate	Undisclosed target	Hematological malignancies					
Multiple RTCC candidates	Undisclosed targets	Immuno-oncology					
ADAPTIR with Novel MOA	Undisclosed targets	Immuno-oncology					

RTCC Preclinical Candidate

ROR-1/ES425

- Targets hematologic malignancies and solid tumors
  - Triple-negative breast cancer, ovarian cancer, NSCL, prostate kidney cancers
- Preclinical in vitro and in vivo proof of concept established
- Improved preclinical PK
- Developing lead candidate

AGENDA

Leadership in Bispecific Antibody Development

- Aptevo today
- What sets us apart
- Summary

Investment Fundamentals

Spin Date: August 1, 2016	
Shares Outstanding	20.2M
Cash Runway	$100M ▪ $65M Today ▪ $35M Future*
Total Revenue (2015)	$34M (Pro Forma) $28M Total Product Sales $6M Contracts, Grants, Collaborations
Total Revenue (Q1 2016)	$8M (Pro Forma)
Estimated Cash Burn	~$50M - $55M (2016 Pro Forma)

*Includes $20M in cash from Emergent Biosolutions to be paid by August 1, 2017 and $15M in term loan financing from MidCap Financial

Key Milestones – 18-24 Months

Development

- Complete Phase 1 study of MOR209/ES414 and advance into Phase 2 development in partnership with MorphoSys
- Generate new ADAPTIR-based RTCC candidates
- Expand application of ADAPTIR-based candidates into new MOA
- Advance new preclinical ADAPTIR-based candidates into the clinic

Operational/Financial

- Capture incremental market share of Hemophilia B market with expanded sales of IXINITY
- Expand ex-US commercial market opportunities through new regulatory filings in select foreign jurisdictions
- Continue current and initiate future partnering discussions around product candidates

Multiple Upcoming Valuation Catalysts

Why Aptevo?

1. Established leadership and capabilities in protein-based therapies for cancer
2. Proprietary, versatile, differentiated ADAPTIR™ technology platform
3. Broad pipeline of clinical and preclinical development candidates
4. Capital efficient model with commercial product portfolio to support R&D funding
5. Solid financial position - $65M cash from Emergent and $35M term loan

Appendix

Intellectual Property Estate

APTEVO owns or exclusively licenses patent rights protecting

- IXINITY
- ADAPTIR
- otlertuzumab
- MOR209/ES414
- ES210
- ES425
- 5E3mAb

APTEVO'S General Patent Filing and Prosecution Strategy

- Will seek patent protection on all products and platforms
  - Exception – existing hyperimmune products
- Will practice life cycle management
  - File new patent applications as products and related methods evolve
- Will seek broad geographic scope
- Will seek exclusive licenses as available for supporting technologies

Portfolio of Marketed Products

IXINITY®

IXINITY® [coagulation factor IX (recombinant)]

IXINITY® is an intravenous recombinant human coagulation factor IX therapeutic for the control and prevention of bleeding episodes and for perioperative management in adults and children, ≥12 years of age, with Hemophilia B.

What is Hemophilia B? Hemophilia B is a bleeding disorder caused by a mutation on the factor IX gene resulting in a deficiency of clotting factor IX in the blood, which controls bleeding. The primary aim of care is to prevent and treat bleeding by replacement with the deficient clotting factor.

How does IXINITY work? IXINITY contains recombinant coagulation factor IX (trenonacog alfa) which replaces the deficient clotting factor.

IXINITY was approved by the FDA in April 2015 and launched into the market in June 2015.

Portfolio of Marketed Products

WINRHO® SDF

US: [Rho (D) Immune Globulin Intravenous (Human)] Canada: (Rho (D) Immune Globulin (Human) for injection)

WinRho® SDF is a Rh_o(D) Immune Globulin Intravenous (Human) product indicated for use in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage in the treatment of non-splenectomized, Rh_o(D)-positive:

- Children with chronic or acute Immune Thrombocytopenic Purpura (ITP)
- Adults with chronic ITP
- Children and adults with ITP secondary to HIV infection

What is ITP? Immune Thrombocytopenic Purpura (ITP) is a type of autoimmune bleeding disorder. It occurs because of a reduction in cells (platelets) that normally cause blood to clot. Sometimes, ITP occurs after an infection, especially in children.

How does WinRho SDF work? WinRho is a sterile, liquid gamma globulin (IgG) fraction containing antibodies to the Rh_o(D) antigen (D antigen). WinRho has been shown to increase platelet counts through the formation of red blood cell complexes which spare antibody coated platelets from removal.

WinRho SDF has been used to treat ITP in the U.S. since 1995.

Portfolio of Marketed Products

HEPAGAM B®

US: [Hepatitis B Immune Globulin Intravenous (Human)]
Canada: (Hepatitis B Immune Globulin (Human) Injection)

HepaGam B® is the only Hepatitis B Immune Globulin approved by the FDA for the prevention of hepatitis B recurrence following liver transplantation in HBsAg-positive patients. HepaGam B is also approved for post-exposure prophylaxis after acute exposure to the hepatitis B virus (HBV).

What is HBV? HBV causes the liver disease Hepatitis B. The virus interferes with liver functioning and causes pathological damage. A small percentage of infected people cannot get rid of the virus and become chronically infected – these people are at higher risk of death from cirrhosis of the liver and liver cancer.

How does HepaGam B work? HepaGam B is a sterile solution of purified gamma globulin (IgG) fraction of human plasma containing antibodies to hepatitis B surface antigen. HepaGam B provides passive immunization for individuals exposed to the hepatitis B virus, by binding to the surface antigen of the virus and reducing the rate of hepatitis B infection.

HEPAGAM B is the ONLY hepatitis B immune globulin (HBIg) approved by the FDA to both prevent hepatitis B virus (HBV) recurrence following liver transplantation in HBsAg-positive patients and provide post-exposure prophylaxis

Portfolio of Marketed Products

VARIZIG®

US: VARIZIG® [Varicella Zoster Immune Globulin (Human)]
Canada: VariZIG® (Varicella Zoster Immune Globulin (Human))

VARIZIG® is intended for use as post-exposure prophylaxis to reduce the severity of chickenpox infections in high risk patient groups (see respective U.S. and Canadian prescribing information for details).

What is Varicella? Varicella-zoster virus (VZV) causes an illness commonly known as chickenpox. This easily spread disease can be a serious health issue for high risk patient groups. Chickenpox causes a blister-like rash, itching, tiredness, and fever.

How does VARIZIG work? VARIZIG is a sterile lyophilized preparation of purified human immune globulin G (IgG) containing antibodies to VZV that can reduce the severity of varicella infections.

VARIZIG was approved by the FDA in 2012 and is the only approved post exposure treatment for VZV.